Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is N/A as of Tuesday, October 6, 2026.
GROSS MARGIN
N/A
Market Cap
$262.92M
Gross Margin
85.79%
TTM Avg
85.31%
3Y Avg
84.59%
5Y Avg
70.69%
Market Cap
$265.78M
Gross Margin
93.41%
TTM Avg
92.41%
3Y Avg
88.66%
5Y Avg
85.93%
Market Cap
$266.59M
Gross Margin
0.00%
TTM Avg
-131.21%
3Y Avg
-60.86%
5Y Avg
-7.69%
Market Cap
$266.92M
Gross Margin
-94.12%
TTM Avg
-431.85%
3Y Avg
-231.35%
5Y Avg
-189.25%
Market Cap
$261.43M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1258.31%
5Y Avg
-887.92%
Market Cap
$261.27M
Gross Margin
81.22%
TTM Avg
75.50%
3Y Avg
37.75%
5Y Avg
35.00%
Market Cap
$259.56M
Gross Margin
41.38%
TTM Avg
41.46%
3Y Avg
41.37%
5Y Avg
45.85%
Market Cap
$259.49M
Gross Margin
79.45%
TTM Avg
80.09%
3Y Avg
80.50%
5Y Avg
80.39%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Scribe Therapeutics Inc. (SCTX) | $264.25M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | 85.79% | 85.31% | 84.59% | 70.69% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $265.78M | 93.41% | 92.41% | 88.66% | 85.93% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $266.59M | 0.00% | -131.21% | -60.86% | -7.69% |
| Fate Therapeutics, Inc. (FATE)vs › | $266.92M | -94.12% | -431.85% | -231.35% | -189.25% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | 0.00% | 0.00% | -1258.31% | -887.92% |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | 81.22% | 75.50% | 37.75% | 35.00% |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | 41.38% | 41.46% | 41.37% | 45.85% |
| Treace Medical Concepts, Inc. (TMCI)vs › | $259.49M | 79.45% | 80.09% | 80.50% | 80.39% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
N/A
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
